Sagittarius Life Science (3205) reported revenue of NT$37.8 million for Oct 2026, +125.2% year on year and +5.8% from the previous month. Revenue for Jan–Oct 2026 was NT$475.5 million (+47.1% year on year).
In Oct 2026, it ranked No. 110 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$37.8 million | +125.2% | +5.8% |
| Sep 2026 | NT$35.8 million | +71.1% | +1.5% |
| Aug 2026 | NT$35.2 million | -0.4% | +12.1% |
| Jul 2026 | NT$31.4 million | -14.2% | -23.0% |
| Jun 2026 | NT$40.8 million | +5.0% | -53.1% |
| May 2026 | NT$86.9 million | +129.6% | +43.9% |
| Apr 2026 | NT$60.4 million | +67.9% | -1.2% |
| Mar 2026 | NT$61.1 million | +73.9% | +56.5% |
| Feb 2026 | NT$39.1 million | +26.9% | -16.8% |
| Jan 2026 | NT$46.9 million | +34.0% | +169.2% |
| Dec 2025 | NT$17.4 million | -65.3% | +226.7% |
| Nov 2025 | NT$5.3 million | -83.5% | -68.2% |
| Oct 2025 | NT$16.8 million | -52.3% | -19.6% |
| Sep 2025 | NT$20.9 million | -46.1% | -40.9% |
| Aug 2025 | NT$35.4 million | -9.7% | -3.4% |
| Jul 2025 | NT$36.6 million | +0.2% | -5.8% |
| Jun 2025 | NT$38.9 million | +2.5% | +2.6% |
| May 2025 | NT$37.9 million | -4.7% | +5.3% |
| Apr 2025 | NT$36 million | -7.5% | +2.3% |
| Mar 2025 | NT$35.1 million | -2.1% | +14.2% |
| Feb 2025 | NT$30.8 million | -8.1% | -12.2% |
| Jan 2025 | NT$35 million | -29.1% | -30.4% |
| Dec 2024 | NT$50.3 million | +39.5% | +55.2% |
| Nov 2024 | NT$32.4 million | -7.8% | -7.9% |
| Oct 2024 | NT$35.2 million | +2.7% | -9.1% |
Jan–Oct 2026 cumulative: NT$475.5 million (+47.1% YoY)
Other Biotech & Medical companies
Compare with peers: Sagittarius Life Science vs PEC / Sagittarius Life Science vs Lotus Pharm / Sagittarius Life Science vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本月營收成長,主係客戶需求增加所致。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16